MANKIND PHARMA
Back to Income Statement
|
MANKIND PHARMA Last 5 Year Consolidated Net Profit History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Consolidated Net Profit | ₹1,913 Cr | ₹1,991 Cr | ₹1,913 Cr | ₹1,282 Cr | ₹1,433 Cr |
What is the latest Consolidated Net Profit of MANKIND PHARMA ?
| Year | Consolidated Net Profit |
|---|---|
| Mar2026 | ₹1,913 Cr |
| Mar2025 | ₹1,991 Cr |
| Mar2024 | ₹1,913 Cr |
| Mar2023 | ₹1,282 Cr |
| Mar2022 | ₹1,433 Cr |
How is Consolidated Net Profit of MANKIND PHARMA Trending?
| Years | Consolidated Net Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,913 Cr | -3.92 | |
| Mar2025 | ₹1,991 Cr | 4.08 | |
| Mar2024 | ₹1,913 Cr | 49.23 | |
| Mar2023 | ₹1,282 Cr | -10.58 | |
| Mar2022 | ₹1,433 Cr | - | |
Compare Consolidated Net Profit of peers of MANKIND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MANKIND PHARMA | ₹103,473.0 Cr | -2.4% | 1.2% | -3.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹465,711.0 Cr | -0.8% | 3.5% | 14.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹192,376.0 Cr | -1% | 7.3% | 7.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹188,655.0 Cr | -0.9% | 10.1% | 44.6% | Stock Analytics | |
| CIPLA | ₹113,979.0 Cr | -2.1% | -1.8% | -6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,204.7 Cr | -5.8% | -13.2% | -7.7% | Stock Analytics | |
MANKIND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MANKIND PHARMA | -2.4% |
1.2% |
-3.2% |
| SENSEX | -2.7% |
-0.2% |
-8% |
You may also like the below Video Courses